|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Richard A. Gonzalez||Chairman & CEO||7,36M||7,76M||1954|
|Dr. Michael E. Severino||Vice Chairman & Pres||4,29M||N/D||1966|
|Mr. Robert A. Michael||Exec. VP & CFO||3,22M||N/D||1970|
|Ms. Laura J. Schumacher||Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec.||4,2M||N/D||1963|
|Dr. Azita Saleki-Gerhardt||Exec. VP of Operations||N/D||N/D||1963|
|Dr. Thomas J. Hudson||Sr. VP of R&D and Chief Scientific Officer||N/D||N/D||1962|
|Ms. Elizabeth Shea||VP of Investor Relations||N/D||N/D||N/D|
|Mr. Timothy J. Richmond||Exec. VP & Chief HR Officer||N/D||N/D||1966|
|Mr. Henry O. Gosebruch||Exec. VP & Chief Strategy Officer||N/D||N/D||1973|
|Mr. Jeffrey Ryan Stewart||Exec. VP & Chief Commercial Officer||N/D||N/D||1969|
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrÃ¶m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
L'ISS Governance QualityScore di AbbVie Inc. al 26 settembre 2021 è 8. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 5; diritti degli azionisti: 9; retribuzione: 4.